Research News

Combination Niraparib plus Pembrolizumab Shows Promise

(June 18, 2019) Results of new trials, funded in part by OCRA though the Ovarian Cancer Dream Team and published in JAMA Oncology, show that combination niraparib plus pembrolizumab therapy showed promising antitumor activity in patients with…

Read on

OCRA and American Cancer Society Launch New Ovarian Cancer Research Collaboration

Four multidisciplinary teams to be funded to study survivorship (June 13, 2019) In a new collaboration, the American Cancer Society and Ovarian Cancer Research Alliance have joined forces to fund multidisciplinary research projects to explore new…

Read on

Highlights from American Society of Clinical Oncology’s Annual Meeting

(June 7, 2019) OCRA is back from the American Society of Clinical Oncology’s annual meeting in Chicago, where doctors and researchers met to discuss the latest in the care of women with ovarian cancer…

Read on

OCRA Funded Research Identifies Genes Associated with Increased Risk of Ovarian Cancer

(May 21, 2019) Earlier this month, Nature Genetics published a study, in part funded by OCRA, that found 34 genes were connected to women developing the earliest stages of ovarian cancer…

Read on

Highlights from 2019 SGO Annual Meeting on Women’s Cancer

(April 3, 2019) In March, ovarian cancer researchers, clinicians and advocates gathered to attend the much-anticipated Society of Gynecologic Oncology’s (SGO) 50th Annual Meeting on Women’s Cancer, to discuss the latest cutting edge…

Read on

National Comprehensive Cancer Network Updates Guidelines

(March 26, 2019) The NCCN, or the National Comprehensive Cancer Network, recently updated its clinical guidelines for the treatment of ovarian cancers…

Read on

OCRA Funded Study Aims to Increase Efficacy of PARP Inhibitors

(March 20, 2019) The Ovarian Cancer Dream Team, funded in part by OCRA, recently completed a Phase 1b Trial, which combined a PARP inhibitor with an HRR (homologous recombination repair) pathway inhibitor, such as PI3K, in order to increase the…

Read on

Action Alert: Tell Congress to Increase OCRP Funding

(March 19, 2019) Congress is considering a $15 million increase for OCRP funding. Urge YOUR Representative to sign the letter to help push this funding through…

Read on

Lymphadenectomy in Ovarian Cancer Patients Can Be Unnecessary

(March 18, 2019) Before the most recent study on the usage of lymphadenectomy, published earlier this month in the New England Journal of Medicine, it was thought that surgically removing clinically negative lymph nodes had a positive effect on the…

Read on

OCRA-Funded Research Indicates that Stem-Like Cells May Be Key to Preventing Recurrence

(March 15, 2019) Cell Reports recently published a study about a drug that, given in combination with chemotherapy, could greatly increase survival rates of ovarian cancer patients…

Read on

New Therapeutic Approaches for Mucinous Ovarian Cancer

(February 13, 2019) Data from a study conducted by researchers at MD Anderson and Johns Hopkins suggest that an adjuvant gastrointestinal (GI)-based chemotherapy regimen is more beneficial than one that is gynecologic-based in patients with mucinous…

Read on

Drugs to Treat Hypertension May Enhance Ovarian Cancer Drugs

(January 23, 2019) Researchers at Massachusetts General Hospital recently found a correlation between a class of drug used to treat hypertension and longer survival rates in ovarian cancer patients when used with paclitaxel, a drug used to treat…

Read on